CCI
CRL icon

Columbus Circle Investors’s Charles River Laboratories CRL Stock Holding History

Columbus Circle Investors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-14,800
Closed -$1.6M – 192
2017
Q3 		$1.6M Buy
+14,800
New +$1.52M 0.03% 243

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Columbus Circle Investors's CRL Position: Q4 2017 in Review

Columbus Circle Investors sold out of Charles River Laboratories (CRL) in Q4 2017, closing a stake of 22,390 shares — an estimated $2.42M sold.

Columbus Circle Investors first reported a position in CRL in Q4 2013 and held it in 8 quarters. The position peaked at $12.6M in Q1 2014. 339 funds tracked by Wall St. Rank hold CRL as of Q4 2017.

  • Columbus Circle Investors reported no remaining Charles River Laboratories position as of Q4 2017 after selling out during the quarter.
  • Columbus Circle Investors sold 22,390 Charles River Laboratories shares in Q4 2017, an estimated $2.42M.
  • Columbus Circle Investors first reported a position in Charles River Laboratories in Q4 2013 and held it in 8 quarters.
  • Columbus Circle Investors's Charles River Laboratories position peaked at $12.6M in Q1 2014.
  • 339 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2017.

Based on Columbus Circle Investors's 13F filing for Q4 2017, filed 2 Feb 2018.